Follow the LIQUIDIA CORPORATION share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €6.1bn. The latest transaction was disclosed on 21 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Canaan VIII LP. The full history is accessible without an account.
8
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate LIQUIDIA CORPORATION Buy (bullish), based on 8 analysts. Average price target: US$107.75.
32Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 16,013 of 29,020 companies
49.1
score / 100
Value
32
Quality
66
FCF yld-0.7%
Earn yld-1.1%
EV/EBITDA·
ROE132%
Gross mgn92%
Net mgn-44%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
200,000 shares@ US$65.000.20% mcap33.4% of flowcommonSEC144:0001969223-26-000642
8 of 8 declarations
About LIQUIDIA CORPORATION
Liquidia Corporation is a company focused on developing innovative therapies for the treatment of respiratory diseases. It utilizes its nanoparticle technology platform to enhance drug delivery.